Global Partnerships

to combat Neglected Tropical Diseases

Shinjiro HAMANO M.D., Ph.D.
Institute of Tropical Medicine (NUITM), Nagasaki University
shinjiro@nagasaki-u.ac.jp  TEL +81-95-819-7822
Introduction of the Speaker (Shinjiro HAMANO)

- 1987-1993  School of Medicine, Kumamoto University (M.D.)
- 1993-1997  Graduate School of Biomedical Sciences, Kyushu University (Ph.D.)
- 1997-2004  Assistant Professor, Kyushu University
- 2004-2006  Research Associate, Virginia State University (2 years)
- 2006-2009  Assistant Professor, Kyushu University
- 2009-      Professor, Institute of Tropical Medicine (NEKKEN), Nagasaki University

- His research interests are tropical infectious diseases and host defense mechanisms to microbes, especially parasites. Besides the immunological approach, he conducts field studies on neglected tropical diseases, especially leishmaniasis and schistosomiasis. in Asia and Africa.
- Since 2020, he has been involved in a new international multidisciplinary collaboration to develop “A schistosomiasis rapid diagnostic test” with FIND, LUMC, Merck (MGHI) etc (G2020-104). In addition, he also dedicated himself to develop diagnostic tools targeting schistosomiasis with Lygature and LUMC (T2017-272, DTECT-Schisto) with the support by the GHIT.
- He has also contributed to developing live-attenuated prophylactic vaccines for leishmaniasis (G2015-115 and G2018-102) and trypanosomiasis (G2019-102) using CRISPR gene editing and leishmanin skin test for detection of Leishmania exposure and immunity (G2019-213).
The tropics, the most ecologically diverse region on the Earth, presents an ongoing complexity of tropical diseases and other health problems. In view of the remarkable advances made in the field of international exchange in recent years, it is imperative that these problems be addressed from a global perspective. Based on this understanding, the Institute of Tropical Medicine, Nagasaki University, aims to overcome tropical diseases, particularly infectious diseases, and the various health problems associated with them, in cooperation with related institutions, to strive for excellence in the following areas:

1. Leading research in tropical medicine and international health
2. Global contribution to disease control and health promotion in the tropics by applying the fruits of the research
3. Cultivation of the researchers and specialists in the fields mentioned above
The GHIT facilitate international partnerships that bring Japanese innovation, investment, and leadership to the global fight against infectious diseases and poverty in the developing world.

<table>
<thead>
<tr>
<th>Drug Development</th>
<th>Vaccine Development</th>
<th>Diagnostic Development</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Target Research Platform</strong></td>
<td><strong>Target Research Platform</strong></td>
<td><strong>Target Research Platform</strong></td>
</tr>
<tr>
<td>Drug Identification</td>
<td>Antigen Identification</td>
<td>Concept Development</td>
</tr>
<tr>
<td>Target Validation</td>
<td>Vaccine Concept Development</td>
<td>Technical feasibility</td>
</tr>
<tr>
<td>Hit Identification</td>
<td>Technology Platform Identification</td>
<td>Development Feasibility</td>
</tr>
<tr>
<td>Load Identification</td>
<td>Preclinical Development</td>
<td>Product Design</td>
</tr>
<tr>
<td><strong>Product Development Platform</strong></td>
<td><strong>Product Development Platform</strong></td>
<td><strong>Product Development Platform</strong></td>
</tr>
<tr>
<td>Lead Optimization</td>
<td>Proclinical Development</td>
<td>Product Design</td>
</tr>
<tr>
<td>Preclinical Development</td>
<td>Clinical Development</td>
<td>Product Development</td>
</tr>
<tr>
<td>Phase 1 Clinical Development</td>
<td>Phase 2 Clinical Development</td>
<td>Phase 3 Clinical Development</td>
</tr>
<tr>
<td>Phase 3 Clinical Development</td>
<td>Registration</td>
<td>Registration</td>
</tr>
</tbody>
</table>

- **Drug Development**
  - Leishmaniasis Vac: G2015-115 → G2018-201
  - Schistosomiasis: G2019-102
  - Chagas Disease: G2019-102

- **Vaccine Development**
  - Leishmaniasis Vac: G2016-272
  - Schistosomiasis: G2019-213
  - Chagas Disease: G2019-213

- **Diagnostic Development**
  - Schistosomiasis: T2017-272
  - Skin test for Leishmaniasis: G2019-213
  - Schistosomiasis CAA-RDT: G2020-104

Institutions involved:
- FIND, LUMC, Merck, Mologic, KEMRI & UERM
- OSU, McGill Univ., US FDA, NIAID/NIH
- Gennova Biopharmaceuticals
- OSU, CIDR-Ecuador
A list of specific questions for the GHIT fund - PDPs webinar series session 4 (FIND)

1. How did we first learn about PDPs and the PDPs of our session (FIND)?

2. Present about the project(s) working with PDPs/FIND (on-going and past), preferably a GHIT-related project.
   (e.g. how the partnership/project started, the PDP’s and your organization’s role in the project, its merits/impact to your organization)

3. Lessons learned and challenges from the partnership and share how these lessons can be implemented in future projects with PDPs and/or our organization’s R&D activities.
We learnt about PDPs through the GHIT project to develop live attenuated prophylactic vaccines for leishmaniasis.
Innovative approach and achievements

- Using CRISPR-Cas, generated marker free centrin gene deficient L. major (LmCen⁻/⁻).
- Demonstrated safety of LmCen⁻/⁻ in immunodeficient host, their failure to survive in sand fly vector and inability to revert to virulence after multiple animal passages.
- Demonstrated efficacy of LmCen⁻/⁻ parasites in preventing sand fly-transmitted cutaneous (CL) as well as visceral leishmaniasis (VL) in mice and hamsters.
- Showed that LmCen⁻/⁻ parasites induce protective immune response and parasite-specific effector memory T cells.
- Using CRISPR-Cas, generated marker free centrin gene deficient L. mexicana (LmexCen⁻/⁻).

Publications


https://www.ghitfund.org/investment/portfoliodetail/detail/135/en
Further Achievements

- Developing Master Cell Bank and Working Cell Bank for LmCen\(^{-}\) parasites at ATCC, USA for manufacturing of cGMP product in an endemic country.
- Validating the assays for final characterization of cGMP LmCen\(^{-}\) product.
- Preparing regulatory dossier for Phase 1 study with regulatory authorities in the US.
- Initiated discussions with our Indian vaccine manufacturer for Phase 1 studies in the India.
- Developed GLP material for *L. donovani* antigens for Skin Test for leishmaniasis as a surrogate marker for immunity. (G2019-213).
We learnt about the PDP with FIND through GHIT-related project.

**Drug Development**

- **Target Research Platform**
  - Target Identification
  - Target Validation
  - Hit Identification
  - Lead Identification

- **Screening Platform**

- **Hit-to-Lead Platform**

- **Product Development Platform**
  - Lead Optimization
  - Preclinical Development
  - Phase 1 Clinical Development
  - Phase 2 Clinical Development
  - Phase 3 Clinical Development
  - Registration

**Vaccine Development**

- **Target Research Platform**
  - Antigen Identification
  - Vaccine Concept Development
  - Technology Platform Identification

- **Product Development Platform**
  - Preclinical Development
  - Phase 1 Clinical Development
  - Phase 2 Clinical Development
  - Phase 3 Clinical Development
  - Registration

**Diagnostic Development**

- **Target Research Platform**
  - Concept Development
  - Technical Feasibility
  - Development Feasibility

- **Product Development Platform**
  - Product Design
  - Product Development
  - Product Validation
  - Registration

**Projects**

- **G2015-115 → G2018-201** Leishmaniasis Vac
- **G2019-102** Chagas Disease Vac

**Partners**

- OSU, McGill Univ., US FDA, NIAID/NIH
- Gennova Biopharmaceuticals
- OSU, CIDR-Ecuador

**Additional Projects**

- **T2017-272** Schistosomiasis DTECT-Schisto (Ab detection) with Lygature, LUMC
- **G2019-213** Skin test for Leishmaniasis
- **G2020-104** Schistosomiasis CAA-RDT with FIND, LUMC, Merck, Mologic, KEMRI & UERM
Globally prevalent schistosomiasis (230 million people are infected)

Global Health Problem
- Schistosomiasis affects 230 million people worldwide, including many children <14yrs of age
- Control programs largely based on Mass Drug Administration (MDA) with praziquantel (PZQ)
- Efforts move from control towards elimination of schistosomiasis (WHO Roadmap)

Unmet Need
- New diagnostic or monitoring tools are urgently needed to support, monitor and sustain schistosomiasis control and elimination programs.

Current diagnostic methods have limitations:
- Insensitive for low-intensity infections & not suitable for post-MDA application AND/OR
- Not able to discriminate between current and past infection AND/OR
- Not able to detect infection with different Schistosoma species AND/OR
- Not in rapid test or field-applicable format (invasive, based on blood collection)

Lancet Infect Dis. 2017 Feb;17(2):e42-e48
Human schistosomiasis in the post mass drug administration era
Schistosomiasis control toward elimination

How can we monitor and survey (re)transmission of schistosomiasis in pre- and post elimination settings?
Partners DTECT-Schisto (T2017-272)

Development of defined antigens for detection of *schistosoma* infection-specific antibodies in blood and urine

1. Diagnostic Ab response profiles and protein/glycan targets have been identified.
2. Data analysis to identify and validate specific targets and use cases is ongoing.
SPOTLIGHT ON SCHISTOSOMIASIS
RAPID TESTS TO SUPPORT DISEASE CONTROL & ELIMINATION

SUPPORTING NATIONAL PROGRAMMES TO MONITOR THE IMPACT OF MASS DRUG ADMINISTRATION CAMPAIGNS AND PRECISION MAPPING EFFORTS

GHIT grant approved July 2020
Consortium of 8 partners
In 2021, first field evaluations of prototype in Kenya and the Philippines (led by NUITM) yielded very encouraging results
Further development of the CAA RDT is required to meet the sensitivity targets, with a final field evaluation required prior to design-lock and transfer to manufacturing – planned for Q2/3 2022
FIND in collaboration with GHIT and the Merck Global Health Institute are developing an access strategy for the SCH CAA RDT

NUITM is monitoring the field studies of the prototype in the Philippines and will manage the clinical trials with the support from FIND.
Lessons learned and challenges from the partnership

**Lessons learned:**

- Making international multidisciplinary team with complementary expertise is critical, which can bring the projects forward from academic research to the product development with overcoming scientific, technical, and regulatory hurdles.
- Managing multi-stakeholder consortia with leadership and coordination is essential and crucial.

**Challenges:**

- Establishing strong relationships in the absence of in-person meetings. The SCH CAA RDT project got funded in July 2020, in the first year of COVID-19. To this day, we have not had the chance to meet the FIND team nor any of other partners in person. Yet, we’ve successfully completed the first field evaluations with very promising results.
- COVID-19: having to monitor field-based studies outside of Japan with new partners. We had to find innovative ways to work around this, by developing new tools, and hiring a clinical research associate to be present at the field site, instead of us.
How can these lessons be implemented in future projects with PDPs and/or our organization’s R&D activities?

- **In future projects with PDPs**
  - We will try having an independent “broker” with expertise in managing multi-stakeholder consortia in health R&D and access.
  - We need to be more familiar with the regulatory processes in FDA, EMA, WHO or other national authorities for the development of new vaccines, drugs and diagnoses.

- **Our organization’s R&D activities**
  - Our organization will promote and strengthen public-private partnership (PPP) for sustainable, efficient, and fruitful development of R&D activities.